Accuray (ARAY) to Release Earnings on Wednesday

Accuray (NASDAQ:ARAY) is anticipated to release its Q2 2026 results after the market closes on Wednesday, February 4th. Analysts expect Accuray to post earnings of ($0.11) per share and revenue of $100.86 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 4:30 PM ET.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.13). The company had revenue of $93.94 million for the quarter, compared to analyst estimates of $91.34 million. Accuray had a negative return on equity of 34.06% and a negative net margin of 4.28%. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Accuray Stock Up 2.4%

Shares of ARAY opened at $0.83 on Wednesday. Accuray has a fifty-two week low of $0.78 and a fifty-two week high of $2.95. The company’s fifty day moving average is $0.92 and its two-hundred day moving average is $1.29. The firm has a market cap of $93.57 million, a PE ratio of -5.16 and a beta of 1.10. The company has a quick ratio of 0.76, a current ratio of 1.56 and a debt-to-equity ratio of 2.06.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its position in shares of Accuray by 762.3% in the 1st quarter. AQR Capital Management LLC now owns 162,922 shares of the medical equipment provider’s stock worth $292,000 after purchasing an additional 144,029 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Accuray by 429.3% during the first quarter. Jane Street Group LLC now owns 91,944 shares of the medical equipment provider’s stock valued at $165,000 after purchasing an additional 74,574 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Accuray by 7.8% in the 2nd quarter. Geode Capital Management LLC now owns 2,421,724 shares of the medical equipment provider’s stock worth $3,318,000 after acquiring an additional 174,703 shares during the period. Marshall Wace LLP bought a new position in Accuray in the 2nd quarter worth approximately $820,000. Finally, Sei Investments Co. raised its stake in shares of Accuray by 83.0% during the second quarter. Sei Investments Co. now owns 93,843 shares of the medical equipment provider’s stock valued at $129,000 after purchasing an additional 42,557 shares in the last quarter. 64.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ARAY shares. Wall Street Zen upgraded Accuray from a “sell” rating to a “hold” rating in a report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Accuray in a research note on Monday, December 29th. Finally, BTIG Research decreased their target price on Accuray from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, November 6th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Accuray presently has an average rating of “Hold” and a consensus target price of $4.00.

About Accuray

Accuray Incorporated (NASDAQ: ARAY) is a global medical device company that develops, manufactures and markets innovative radiation therapy solutions for the treatment of cancer. The company’s flagship products include the CyberKnife® System, a robotic radiosurgery platform offering sub-millimeter precision, and the TomoTherapy® System, which combines helical computed tomography (CT) imaging with intensity-modulated radiation therapy (IMRT). More recently, Accuray introduced the Radixact® System, an advanced iteration of its TomoTherapy technology designed to enhance treatment speed and clinical workflow.

Accuray’s suite of products enables clinicians to deliver highly targeted radiation doses while minimizing exposure to surrounding healthy tissue.